In metabolic disorders characterized by hyperglycemia, such as in both types 1 and 2 diabetes, increased expression and activity of SGLT1 contributes to increased glucose absorption in the small intestine and, therefore, represents a pathophysiological factor of hyperglycemia. This evidence concerns the gene SLC5A1 and metabolic disease.